Compile Data Set for Download or QSAR
maximum 50k data
Found 72 of ic50 data for complexid = 346
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525707(US11174250, Example 125)
Affinity DataIC50:  49nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525675(US11174250, Example 93)
Affinity DataIC50:  197nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525693(US11174250, Example 111)
Affinity DataIC50:  203nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525589(US11174250, Example 7)
Affinity DataIC50:  216nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525628(US11174250, Example 46)
Affinity DataIC50:  290nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525706(US11174250, Example 124)
Affinity DataIC50:  293nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525582(US11174250, Example 32 | US11174250, Example Table...)
Affinity DataIC50:  332nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525627(US11174250, Example 45)
Affinity DataIC50:  514nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525609(US11174250, Example 27)
Affinity DataIC50:  529nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525664(US11174250, Example 82)
Affinity DataIC50:  549nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525578(US11174250, Example 73 | US11174250, Example Table...)
Affinity DataIC50:  592nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525578(US11174250, Example 73 | US11174250, Example Table...)
Affinity DataIC50:  592nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525692(US11174250, Example 110)
Affinity DataIC50:  607nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525583(US11174250, Example 1)
Affinity DataIC50:  764nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525608(US11174250, Example 26)
Affinity DataIC50:  779nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525659(US11174250, Example 77)
Affinity DataIC50:  907nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example 2 | US11174250, Example Table4...)
Affinity DataIC50:  939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example 2 | US11174250, Example Table4...)
Affinity DataIC50:  939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525575(US11174250, Example 2 | US11174250, Example Table4...)
Affinity DataIC50:  939nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525585(US11174250, Example 3)
Affinity DataIC50:  966nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525672(US11174250, Example 90)
Affinity DataIC50:  1.09E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525648(US11174250, Example 66)
Affinity DataIC50:  1.10E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525652(US11174250, Example 70)
Affinity DataIC50:  1.11E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525649(US11174250, Example 67)
Affinity DataIC50:  1.15E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525619(US11174250, Example 37)
Affinity DataIC50:  1.30E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525642(US11174250, Example 60)
Affinity DataIC50:  1.41E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525598(US11174250, Example 16)
Affinity DataIC50:  1.47E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525590(US11174250, Example 8)
Affinity DataIC50:  1.48E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525631(US11174250, Example 49)
Affinity DataIC50:  1.57E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525613(US11174250, Example 31)
Affinity DataIC50:  1.74E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525656(US11174250, Example 74)
Affinity DataIC50:  1.75E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525632(US11174250, Example 50)
Affinity DataIC50:  1.79E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525650(US11174250, Example 68)
Affinity DataIC50:  1.89E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525581(US11174250, Example 116 | US11174250, Example Tabl...)
Affinity DataIC50:  1.90E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525658(US11174250, Example 76)
Affinity DataIC50:  1.90E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525653(US11174250, Example 71)
Affinity DataIC50:  2.07E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525657(US11174250, Example 75)
Affinity DataIC50:  2.09E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525695(US11174250, Example 113)
Affinity DataIC50:  2.10E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525597(US11174250, Example 15)
Affinity DataIC50:  2.25E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525624(US11174250, Example 42)
Affinity DataIC50:  2.28E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525617(US11174250, Example 35)
Affinity DataIC50:  2.39E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525629(US11174250, Example 47)
Affinity DataIC50:  2.39E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525621(US11174250, Example 39)
Affinity DataIC50:  2.51E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525588(US11174250, Example 6)
Affinity DataIC50:  2.51E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525678(US11174250, Example 96)
Affinity DataIC50:  2.53E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525651(US11174250, Example 69)
Affinity DataIC50:  2.89E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525625(US11174250, Example 43)
Affinity DataIC50:  3.25E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525669(US11174250, Example 87)
Affinity DataIC50:  3.89E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525681(US11174250, Example 99)
Affinity DataIC50:  3.99E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534](Human)
Propellon Therapeutics

US Patent
LigandPNGBDBM525620(US11174250, Example 38)
Affinity DataIC50:  3.99E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 72 total ) | Next | Last >>
Jump to: